Analysts expect Parabilis Medicines, Inc. to report revenue of 796,282.50 for Q4 26, against a range of 748,437.07 to 844,127.93. The most recent reported quarter, Q3 26, came in at 2.11 M, a 499.2% beat against the 352,145.62 consensus.
| Metric | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 |
|---|---|---|---|---|---|---|---|
| Reported (Actual) | 0.00 | 124,000.00 | 2.11 M | - | - | - | - |
| High Estimate | - | 18.15 M | 385,025.81 | 844,127.93 | 1.80 M | 2.55 M | 2.72 M |
| Low Estimate | - | 16.10 M | 319,265.43 | 748,437.07 | 1.53 M | 2.15 M | 2.24 M |
| Consensus Estimate | - | 17.12 M | 352,145.62 | 796,282.50 | 1.67 M | 2.35 M | 2.48 M |
Analysts expect Parabilis Medicines, Inc. to report earnings per share of -0.39 for Q4 26, against a range of -0.42 to -0.36. The most recent reported quarter, Q3 26, came in at -0.36, a 5.9% miss against the -0.34 consensus.
| Metric | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 |
|---|---|---|---|---|---|---|---|
| Reported (Actual) | -0.72 | -2.32 | -0.36 | - | - | - | - |
| High Estimate | - | -0.15 | -0.32 | -0.36 | -0.39 | -0.37 | -0.36 |
| Low Estimate | - | -0.19 | -0.36 | -0.42 | -0.43 | -0.41 | -0.40 |
| Consensus Estimate | - | -0.17 | -0.34 | -0.39 | -0.41 | -0.39 | -0.38 |
Pull Wall Street consensus for Parabilis Medicines, Inc. (high, low and consensus estimates alongside reported actuals) into your own models and apps with the Business Quant Estimates API. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/estimates?ticker=PBLS&mode=revenue&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/estimates"
params = {"ticker": "PBLS", "mode": "revenue", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/estimates?ticker=PBLS&mode=revenue&api_key=YOUR_API_KEY");
const data = await res.json();